GPP
UTHR icon

Great Point Partners’s United Therapeutics UTHR Stock Holding History

Great Point Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-300,000
Closed -$35.2M – 46
2017
Q3 		$35.2M Buy
+300,000
New +$38.3M 6.84% 2

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Great Point Partners's UTHR Position: Q4 2021 in Review

Great Point Partners sold out of United Therapeutics (UTHR) in Q4 2021, closing a stake of 86,667 shares — an estimated $16M sold.

Great Point Partners first reported a position in UTHR in Q2 2018 and held it in 13 quarters. The position peaked at $75M in Q2 2020. 416 funds tracked by Wall St. Rank hold UTHR as of Q4 2021.

  • Great Point Partners reported no remaining United Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Great Point Partners sold 86,667 United Therapeutics shares in Q4 2021, an estimated $16M.
  • Great Point Partners first reported a position in United Therapeutics in Q2 2018 and held it in 13 quarters.
  • Great Point Partners's United Therapeutics position peaked at $75M in Q2 2020.
  • 416 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2021.

Based on Great Point Partners's 13F filing for Q4 2021, filed 14 Feb 2022.